Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06788912 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)
A Phase 2 study of Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06788912: Recruiting Phase 2 study of Lung Neoplasm Malignant, sponsored by Merck Sharp & Dohme.
NCT06788912 is a Phase 2 study of Lung Neoplasm Malignant that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06788912, a Phase 2 study of Lung Neoplasm Malignant, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of living cancer cells in the tumor removed during surgery.
Primary Outcome
pCR is defined as absence of residual viable invasive cancer on hematoxylin- and eosin-stained slides of the resected lung specimen and lymph nodes.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Gemcitabine
- DRUG Sacituzumab tirumotecan
- BIOLOGICAL Pembrolizumab (neoadjuvant)
Study Locations (20)
Other
- Országos Korányi Pulmonológiai Intézet ( Site 0060) - Budapest
- Ospedale San Raffaele. ( Site 0171) - Milan
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175) - Milan
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174) - Roma
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 0162) - Santiago
- FALP ( Site 0161) - Santiago
- Bradfordhill ( Site 0160) - Santiago
Attica
- Alexandra General Hospital of Athens Oncology-Hematology Unit ( Site 0203) - Athens
- ATTIKON GENERAL UNIVERSITY HOSPITAL-Oncology ( Site 0202) - Athens
- Metropolitan Hospital-4th Oncology Dept ( Site 0201) - Athens
Alabama
- Southern Cancer Center (SCC) ( Site 8004) - Daphne
California
- Sansum Clinic (Ridley Tree) ( Site 8012) - Santa Barbara
Maryland
- MedStar Franklin Square Medical Center ( Site 0033) - Baltimore
Oregon
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8006) - Eugene
Virginia
- Virginia Cancer Specialists (VCS) ( Site 8002) - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2032-02-06 |
| Phase | Phase 2 |
What NCT06788912 shows while recruiting
NCT06788912 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Lung Neoplasm Malignant appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT06788912 names 20 study sites across 13 states, led by Other, Region M. de Santiago, Attica.
Frequently Asked Questions
What is clinical trial NCT06788912 about?
NCT06788912 is a clinical study titled "Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)". The main goals are after treatment given before surgery, to measure the number of people who have no signs of cancer cells in tumors and lymph nodes removed during surgery; and to learn about whether the cancer gets smaller or goes away by measuring the number of people with a certain number of livi...
What is the current status of trial NCT06788912?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-03-20. Estimated completion is 2032-02-06.
What conditions does trial NCT06788912 study?
This clinical trial studies the following conditions: Lung Neoplasm Malignant.
What interventions are being tested in trial NCT06788912?
The interventions under investigation include: Cisplatin (DRUG), Pemetrexed (DRUG), Gemcitabine (DRUG), Sacituzumab tirumotecan (DRUG), Pembrolizumab (neoadjuvant) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06788912?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06788912 being conducted?
This trial has 20 study locations across Alabama, California, Maryland, Oregon, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Neoplasm Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06788912's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI